Phase 3 study to be initiated for second long-acting injectable antipsychotic using MedinCell’s technology

Teva Pharmaceuticals has notified MedinCell that it made the decision to initiate the clinical Phase 3 trial for mdc-TJK.

MedinCell will receive immediately a $3 million payment from Teva Pharmaceuticals linked to the project development milestone.

The Phase 3 study will assess the efficacy and safety of potentially the first subcutaneous long-acting Injectable (LAI) formulation of olanzapine for the treatment of patients with schizophrenia.

mdc-TJK follows mdc-IRM (LAI risperidone), the first subcutaneous antipsychotic based on MedinCell’s technology currently under regulatory review by the U.S. FDA, with a launch target set for 2023.